205 related articles for article (PubMed ID: 34532363)
1. Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Yang F; Fu Y; Kumar A; Chen M; Si L; Rojanasarot S
Ann Transl Med; 2021 Aug; 9(15):1226. PubMed ID: 34532363
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Camrelizumab
Zhang Q; Wu P; He X; Ding Y; Shu Y
Front Oncol; 2021; 11():790373. PubMed ID: 34926306
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
Lin YT; Chen Y; Liu TX; Kuang F; Huang P
Cancer Manag Res; 2021; 13():8219-8230. PubMed ID: 34754242
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of camrelizumab versus chemotherapy for the treatment of advanced or metastatic esophageal squamous cell carcinoma.
Li L; Liu X; Huang J; Liu Y; Huang L; Feng Y
J Gastrointest Oncol; 2022 Feb; 13(1):40-48. PubMed ID: 35284115
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma.
Gong J; Shang J; Su D; Qian X; Liu G; Sun Z
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):709-717. PubMed ID: 37190977
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
Cai H; Xu B; Li N; Zheng B; Zheng Z; Liu M
Front Pharmacol; 2021; 12():732912. PubMed ID: 34867339
[No Abstract] [Full Text] [Related]
8. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.
Yang X; Zheng X; Hu S; Huang J; Zhang M; Huang P; Wang J
BMC Cancer; 2024 May; 24(1):654. PubMed ID: 38811891
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China.
Dai H; Wang W; Fan X; Chen Y
Front Med (Lausanne); 2023; 10():1122731. PubMed ID: 36865055
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis.
Liu S; Zhao L; Shi F; Kuai L; Liu R; Tang J
Int J Clin Pharm; 2024 Jun; 46(3):675-683. PubMed ID: 38407692
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors
Liu S; Dou L; Li S
Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.
Zhao Z; Chen T; Zhou Z; Guo R; Liu Q
BMJ Open; 2023 Dec; 13(12):e071832. PubMed ID: 38110377
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
Shao T; Ren Y; Zhao M; Tang W
Front Public Health; 2022; 10():912921. PubMed ID: 36045725
[TBL] [Abstract][Full Text] [Related]
14. Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.
Xiang G; Gu L; Chen X; Wang F; Chen B; Zhao J; Lu Y; Chang F; Zhu Y
Front Public Health; 2021; 9():743558. PubMed ID: 34957008
[No Abstract] [Full Text] [Related]
15. Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Shi F; He Z; Su H; Wang L; Han S
Front Pharmacol; 2022; 13():961347. PubMed ID: 36467065
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Lin YT; Zhou CC; Xu K; Zhang MD; Li X
Ther Adv Med Oncol; 2023; 15():17588359231213621. PubMed ID: 38028139
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China.
Qiao L; Zhou Z; Zeng X; Tan C
Front Pharmacol; 2021; 12():728440. PubMed ID: 34795580
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China.
Liu S; Dou L; Li S
Front Pharmacol; 2023; 14():1055727. PubMed ID: 36937861
[No Abstract] [Full Text] [Related]
19. Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China.
Chen T; Xie R; Zhao Q; Cai H; Yang L
Front Oncol; 2022; 12():746526. PubMed ID: 35936702
[TBL] [Abstract][Full Text] [Related]
20. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Lu S; Lou Y; Rong Y; Huang Z; Lin X; Chen J; Luo K
Clin Drug Investig; 2023 Aug; 43(8):643-652. PubMed ID: 37542611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
